The 2018 Nobel Prize in Medicine and Physiology has been awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. These insights have given rise to a class of medicines that have now entered routine use in the treatment of advanced cancers and have provided a foundation for additional exploration and discovery of pathways critical to modulating the immune response to cancer.
The development of innovative and effective cancer therapies has been and remains one of science and medicine's greatest challenges to improve human health. For decades, therapeutic cancer research was focused on means to impair the ceaseless proliferation that is so intimately part of the malignant phenotype. This has resulted in the successful application of techniques such as radiation therapy, hormonal manipulation, cytotoxic chemotherapy, and most recently, targeted oncogenic pathway inhibition as meaningful cancer therapeutics. As can be easily gleaned, these interventions are all focused on the cancer cell rather than the patient.
In the late 1890s, William Coley, a surgeon in New York at the forerunner of today's Memorial Sloan Kettering Cancer Center, observed that patients who developed post-operative bacterial infections appeared to have better outcomes after cancer surgery than those who did not. Without knowledge of the immune system, he hypothesized that bacterial infection was initiating an inherent resistance to further cancer progression and began therapeutic studies of injection of heatkilled streptococcus and serratia. Such injections resulted in occasional regression but arguably represented the development of the first cancer immunotherapy (Coley's mixed bacterial toxins); however, initial enthusiasm was dampened by the emergence of radiation therapy and then chemotherapeutic drugs combined with a lack of mechanistic understanding of the biology underlying any effect of the toxins. Over the ensuing decades, other examples of immune effects relating to cancer control were observed using Bacillus Calmette-Guerin and then the T cell cytokine interleukin-2. The observation of an admittedly small number of durable regressions (cures?) in patients with a subset of advanced and otherwise fatal malignancies with the use of interleukin-2 represented the first clue that agents that only modulate the immune system could have an impact on cancer in a more profound way.
Despite these earlier insights, intense basic science investigation of the regulation of the immune system would in the end be responsible for the emergence of a treatment approach now known as immunologic checkpoint blockade, which is the subject of this year's Nobel Prize in Physiology or Medicine. To be more specific, Drs. James P. Allison and Tasuku Honjo were awarded the prize for their seminal work on the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1) pathways (Figure 1 ). Both pathways function essentially as molecular ''brakes'' for the immune system, preventing hyperactivation and controlling proliferation. It is logical, therefore, to imagine that interfering with these inhibitory pathways could lead to a more robust immune reaction to cancer. The mechanism of action is complex and still the subject of ongoing investigation, yet it is now clear that the use of agents that block the CTLA-4 and PD-1 pathways have entered the list of conventional approaches to cancer therapy and have already extended countless lives. I will try to address the salient features of both Dr. Allison and Dr Honjo's discoveries below. (Full disclosure-Jim Allison was my chairman for the years he spent at Memorial Sloan Kettering and is someone I consider a visionary mentor, a friend, and a truly badass blues harmonica player. I have met Professor Honjo at meetings and obviously have deep respect and admiration for his scientific work and contributions to the field.)
As background to the discussion, it should be recognized that T cell activation is a multi-step process modulated by a complex regulatory network. Recognition of antigen by the T cell receptor (signal 1) is insufficient for activation and must be accompanied by a costimulatory interaction (signal 2) mediated by CD28 on the T cell ligating a member of the B7 family of costimulatory molecules. CTLA-4 was first described by Pierre Golstein, and its relation to the B7 family of costimulatory molecules was suggested by Peter Linsley (Brunet et al., 1987; Linsley and Golstein, 1996) . Linsley subsequently showed that CTLA-4 bound to B7 with much higher avidity than its better-known activating ligand, CD28. Jim Allison, already an eminent immunologist and well known for important studies of the T cell receptor and CD28-based costimulation, made his first major contribution to the study of CTLA-4 with a 1995 publication (Krummel and Allison, 1995; Walunas et al., 1994) demonstrating that its function was in suppressing T cell responses, and Jeff Bluestone also provided data supporting for that hypothesis around the same time. Genetic proof of the inhibitory role for CTLA-4 came with generation of CTLA-4 knockout mice by the laboratories of Tak Mak and Arlene Sharpe, who independently showed that such animals developed fatal lymphoproliferation because of loss of the critical co-inhibitory molecule (Tivol et al., 1995; Waterhouse et al., 1995) .
The visionary hypothesis, which in my own estimation led to Jim Allison being awarded the Nobel Prize, was that temporary blockade of CTLA-4 with a blocking antibody would perhaps enhance the immune response to tumors. Jim's now seminal publication in 1996, during the time he was leading cancer research at UC Berkeley, was one in which mice bearing syngeneic tumors demonstrated durable tumor regression when treated with a CTLA-4 antibody (Leach et al., 1996) . This clear result provided a firm foundation for emergence of immunologic checkpoint blockade as paradigm shifting intervention in cancer therapy. In an interesting coincidence, this publication appeared on the same page in Science along with a publication about the Drosophila circadian clock written by Dr. Michael Young, who was awarded the Nobel Prize in Physiology and Medicine just last year in 2017. Jim went on doggedly pursuing a means to move CTLA-4 blockade to the clinic. After several years, and ultimately working with Alan Korman and Nils Lonberg and then at Medarex, he saw his science vision translated into a fully human monoclonal antibody to CTLA-4 that entered clinical trials in human cancer patients in 2000. In 2010, that antibody (ipilimumab) became the first drug ever to be shown to improve overall survival in patients with metastatic melanoma (Hodi et al., 2010) . Although the objective response rate was low (15% of patients experienced significant tumor shrinkage), those responses were generally durable, as would be expected for an agent that mechanistically enhances T cell responses. Furthermore, a new class of side effects, termed immune-related adverse events, was described. These toxicities were distinct from those previously associated with other cancer therapies and are best characterized as tissue-specific inflammatory events with symptoms that resemble autoimmune diseases. These unfortunate side effects did, however, present an opportunity to improve our understanding of the science of CTLA-4 and other immune checkpoints to shed further light into treatments for autoimmune disease.
Jim went on to show that CTLA-4 blockade could have both a cell-intrinsic effect on effector T cells and mediate depletion of regulatory T cells. Together with his scientific (and now life) partner, Padmanee Sharma, he has sought to enhance the activity of CTLA-4 blockade through concurrent agonism of the inducible costimulatory (ICOS, another CD28 family member). His work continues today in his home state of Texas at the MD Anderson Cancer Center, where he leads the immunology department and continues to study innovative mechanisms to enhance the immune response to cancer.
Dr. Tasuku Honjo has been recognized for his seminal publication in 1992 describing a new molecule, which he termed programmed death-1 (PD-1) based on its functional role in mediating classical apoptosis in a T cell hybridoma and hematopoetic progenitor cells (Ishida et al., 1992) . Further studies by Honjo's group went on to reveal that loss of PD-1 in mouse models results in development of autoimmune syndromes such as myocarditis and vasculitis, suggesting an important regulatory role for PD-1 in maintaining immune homeostasis. PD-1 is a surface molecule expressed mainly on lymphocytes and other select subsets of hematopoetic cells. A molecule identified by Lieping Chen (Dong et al., 1999) and originally named B7-H1 given its structural homology to the B7 costimulatory molecule was shown to convey immune inhibitory activity. B7-H1 was subsequently demonstrated to be one of the binding partners of PD-1 and is now known as PD-L1. PD-L1 and PD-L2 were identified as the natural ligands for PD-1 by Arlene Sharpe and Gordon Freeman, and their work in collaboration with Tasuku Honjo also showed that PD-1's interaction with its ligands conveyed immune inhibitory activity (Latchman et al., 2001) . Chen, Sharpe, and Freeman (Dong et al., 2002) all also found that in addition to antigenpresenting cells, some tumor cells also expressed B7-H1/PD-L1, bringing forth the hypothesis that tumor cell expression of the ligand could represent a means of evasion from the host immune system, given that ligation of PD-1 resulted in a SHP-2-dependent dampening of signaling from the T cell receptor. Takasu Honjo and Lieping Chen then showed that antibody blockade of PD-L1 or B7-H1 (Iwai et al., 2002; Strome et al., 2003) , respectively, had anti-tumor activity in mouse model systems, setting the stage for the development of antibodies blocking the PD pathway to be developed as human cancer therapeutics.
The first anti-PD-1 antibody (now known as nivolumab) entered clinical trials in 2006 and was followed by pembrolizumab in 2011, and both agents were approved by the US FDA in 2014 after significant durable clinical responses were observed in patients with melanoma, including those who had previously shown refractoriness or resistance to CTLA-4 blockade, in the case of pembrolizumab. What has ensued since then is a rapid emergence of additional antibodies that disrupt the PD-1:PD-L1 interaction and anti-tumor responses in a subset of patients with a broad array of malignancies. As of the time of this writing-in addition to cemiplimab, nivolumab, and pembrolizumab, which block PD-1, the PD-1-blocking antibodies atezolizumab, avelumab, and durvalumab have all received US FDA approval for some type of human cancer. Because several of these agents have been approved alone or in combination for non-small cell lung cancer, which is the leading cause of cancer death in many parts of the world, the impact on the cancer patient population for these agents is staggering. On balance, however, for many of the approved indications, PD-1 pathway blockade results in a clinical tumor regression in 20%-40% of patients, meaning that most patients require other interventions either in combination with PD-1 pathway blockade or instead of it. Two examples are the combination of chemotherapy with pembrolizumab for non-small cell lung cancer and the combination of CTLA-4 blockade with ipilimumab plus nivolumab in melanoma and renal cell carcinoma.
The work of Dr. James Allison and Dr. Tasuku Honjo has been pivotal in the establishment of immunologic checkpoint blockade as a conventional means for durable control of cancer. Although currently available medicines only provide benefit for a subset of patients, the work of these two scientists has opened avenues of research-in both the laboratory and the clinic-that I am confident will expand to many more patients in the future. I thank them for their vision, their persistence, and their inspiration to generations that follow.
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